1804-54-2

Basic information

• Product Name: 4H-3,1-Benzoxazin-4-one, 1-(2,3-dimethylphenyl)-1,2-dihydro-
• CAS NO: 1804-54-2
• Molecular Formula: C16H15NO2
• Molecular Weight: 253.301
• Mol File: 1804-54-2.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 4H-3,1-Benzoxazin-4-one, 1-(2,3-dimethylphenyl)-1,2-dihydro-(CAS DataBase Reference)
• NIST Chemistry Reference: 4H-3,1-Benzoxazin-4-one, 1-(2,3-dimethylphenyl)-1,2-dihydro-(1804-54-2)
• EPA Substance Registry System: 4H-3,1-Benzoxazin-4-one, 1-(2,3-dimethylphenyl)-1,2-dihydro-(1804-54-2)

Safety Data

• Hazardous Substances Data: 1804-54-2(Hazardous Substances Data)

Upstream product

• 118-91-2 ortho-chlorobenzoic acid 
• 87-59-2 2,3-Dimethylaniline 
• 50-00-0 formaldehyd 
• 61-68-7 mefenamic Acid 
• 1804-47-3 sodium N-(2,3-dimethylphenyl)-anthranilate 
• 3188-13-4 ethyl chloromethyl ether 

Downstream Products

• 61-68-7 mefenamic Acid 
• 59338-12-4 (dimethyl-2,3 phenyl)-1 dihydro-1,2 benzothiazine-3,1 thione-4 
• 83389-01-9 (2,3-Dimethyl-phenyl)-(2-[1,3,4]thiadiazol-2-yl-phenyl)-amine 
• 83401-03-0 [1-(2,3-Dimethyl-phenyl)-1,2-dihydro-benzo[d][1,3]thiazin-(4Z)-ylidene]-hydrazine 
• 83388-58-3 3-Amino-1-(2,3-dimethyl-phenyl)-2,3-dihydro-1H-quinazoline-4-thione 

Relevant articles and documents

1,2-dihydro-3,1-benzoxazin-4-one and 4H-1,2-dihydro-pyrido-[2,3-d]-[1,3]-oxazin-4-one derivatives as potential prodrugs. Part I: Synthesis

-

New esters of N arylanthranilic acids

A series of acyloxy and alkyloxymethyl esters of meclofenamic, flufenamic and mefenamic acids has been synthesized and its antiinflammatory, analgesic and antipyretic activities have been compared with those of the corresponding acids and the methyl, β,γ isopropylidenedioxypropyl, and N,N diethylaminoethyl esters. The acyloxy and alkyloxymethyl esters are the most interesting compounds, because they possess pharmacological activity of the same order as that of the corresponding acids and a lower toxicity. The ethoxymethyl ester of N (2,6 dichloro m tolyl)anthranilic acid is presently under clinical investigation.